Dr. Tim T. Lai

Dr. Tahseen Mozaffar is a Professor of Neurology, Orthopaedic Surgery and Pathology and Laboratory Medicine at University of California, Irvine. He is the Director of the UC Irvine-MDA ALS and Neuromuscular Center and the Director of the Division of Neuromuscular Diseases. Dr. Mozaffar serves as chair of one of the biomedical committees and the institutional liaison for Trials Innovation Hub for the Center for Translational Sciences Award (CTSA) at University of California, Irvine. He is the Principal Investigator for UCI-NEXT, the NeuroNEXT award to the University of California, Irvine, one of 25 such NeuroNEXT sites funded by the NINDS/NIH.. Dr. Mozaffar is highly rated in 32 conditions, according to our data. His clinical expertise encompasses Pompe Disease, Inclusion Body Myositis, Myositis, Limb-Girdle Muscular Dystrophy, and Thymectomy. Dr. Mozaffar is board certified in Board Certification In Neurology, 1996-2026, Board Certification In Neuromuscular Medicine, 2008-2028, and Board Certification In Clinical Neuromuscular Pathology, 2015 - 2025. Dr. Mozaffar is currently accepting new patients.

Dr. Namita Goyal is a UCI Health neurologist with board certifications in neurology, electrodiagnostic medicine and neuromuscular medicine. Dr. Goyal is highly rated in 19 conditions, according to our data. Her clinical expertise encompasses Inclusion Body Myositis, Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), Myositis, and Primary Lateral Sclerosis. Dr. Goyal is board certified in CA State Medical License 2012 - 2024 and MA State Medical License 2006 - 2023.

Dr. Daniela A. Bota is a UCI Health neuro-oncologist who specializes in the treatment of primary and metastatic brain and spinal cord tumors, as well as in the neurological complications of cancers.She earned her medical degree at Carol Davila University of Medicine and Pharmacy in Bucharest, Romania. She completed a residency in neurology at University of Kansas Medical Center in Kansas City, followed by a fellowship in neuro-oncology at Duke University School of Medicine in Durham, N.C.Bota's academic research and clinical practice focus on innovative treatments for brain malignancies. She currently serves as a principal investigator for numerous studies including novel glioblastoma stem-cell targeted chemotherapy agents, cellular immunotherapy studies and wearable devices. She consults for multiple companies involved in developing drugs, cellular therapies and devices for human use. In support of these efforts, Bota’s translational research lab investigates potential therapies for malignant gliomas.She also serves as vice dean for Clinical Research at theUCI School of Medicineand director of theUCI Alpha Stem Cell Clinic. Dr. Bota is highly rated in 24 conditions, according to our data. Her clinical expertise encompasses Glioblastoma, Astrocytoma, Glioma, and Brain Tumor.